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Viral hepatitis has been a major problem for 
public health workers and for blood bankers. There 
is much to be learned despite recent major advances 
in the natural history of the disease, in some of its 
epidemiological characteristics, and particularly in its 
laboratory diagnosis. These discoveries will signifi-
cantly reduce the rate of posttransfusion hepatitis. A 
complete solution of the overall hepatitis problem 
will be attained only when the causative role of the 
agent, presumably a virus, has been conclusively 
demonstrated. This will in turn produce more sensi-
tive and specific diagnostic procedures and lead to 
the development of effective, preventive and thera-
peutic measures. Specific laboratory diagnosis of 
hepatitis became possible with the discovery of Aus-
tralia antigen-a term used in 1964 ( 4) by its dis-
coverer Baruch Blumberg. The observation that 
Australia antigen or Au-1 was intimately related to 
hepatitis B virus stimulated large numbers of in-
vestigators who developed overlapping systems of 
nomenclature. Some of these terms, including those 
recommended by the Committee on Viral Hepa-
titis of the Natural Research Council, are given in 
Table 1. Henceforth, the symbol HB Ag will be used 
as the synonym to Au-1. 
The discovery of HB Ag has provided a specific 
marker of infection with serum hepatitis, the most 
common cause of posttransfusion hepatitis. This in 
tum has permitted a partial solution to the blood 
* Presented by Dr. Hossaini at the 44th Annual Mc-
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bankers' dilemma, namely, the detection of HB Ag 
carriers before blood is collected for infusion. 
The frequency of HB Ag in different blood 
donor populations in the U. S. has been estimated 
to be 0.1-0.5% among volunteer donors, and up to 
2 % among paid donors of commercial blood banks 
(6, 9, 14, 15, 16) . In other words, blood collected 
from the latter group may have as high as 20 times the 
risk of transmitting hepatitis as that obtained from 
volunteer donors. A list of techniques for the detec-
tion of HB Ag is presented in Table 2, including their 
relative sensitivity in reference to agar gel diffusion 
(AGD) and the time required for results to be 
obtained. 
AGD was the ,first method available ( 3). This 
method lacks sensitivity. Another disadvantage is 
that it requires a minimum of one to seven days of 
incubation before any results are seen. Moreover, it 
requires that both antigen and antibody be sufficiently 
potent and also of approximately equivalent concen-
tration; otherwise, the results may be falsely negative. 
AGD has the significant advantage, however, in that 
it can discriminate between the components in com-
plex mixtures. It offers a direct demonstration of 
identity, partial identity or nonidentity between dif-
ferent antigens or antibody reactants. In addition, 
sensitivity may be increased by certain modifications. 
Precipitation lines of identity, partial identity, and 
nonidentity on an agar gel plate are depicted in 
figure 1. 
Counterelectrophoresis (CEP) is the most com-
monly used version of the immunoelectrophoresis 
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TABLEl 
VIRAL HEPATITIS- NOMENCLATURE 
Old Terms 
Virus B 
Serum hepatitis 
(SH) 
Posttransfusion 
hepatitis (PTH) 
Long incubation 
New Terms 
SH antigen 
Au/ SH antigen 
Hepatitis antigen 
(HA) 
disease HAA 
Hemologous serum 
jaundice MS-2 
Syringe jaundice 
Virus A 
Short incubation MS-I 
disease 
Infectious hepatitis 
(IH) 
Acute catarrhal 
jaundice 
Epidemic jaundice 
Epidemic hepatitis 
Committee on Viral 
Hepatitis Div. Med. 
Sc., NAS- National 
Research Council 
Hepatitis B virus, 
HBV 
Hepatitis B antigen, 
HBAg 
Hepatitis B anti-
body, HB Ag or 
anti-HB Ag 
Hepatitis A virus, 
HAV 
procedures. The principle of this method is some-
what more difficult to understand than AGD al-
though it is as easy to perform. It has the advantage 
of requiring only 30 minutes to two hours to obtain 
results (8, 10). Like AGD, the CEP test utilizes agar 
gel coated slides and the reactions appear as pre-
cipitation lines. 
Fig. 
SCHEMATIC REPRESENTATION OF PRECIPITATION 
LINES ON AGAR GEL PLATES SHOWING 
VARIOUS IMMUNOLOGICAL RELATIONSHIPS 
Non Identity Partial Identity Identity 
The complement-fixation (CF) test is consider-
ably more complicated than AGD and CEP tech-
nically and in principle. It is not, therefore, as prac-
tical for mass screening. Generally it is more sensitive 
than CEP (11, 12, 18, 20). The sensitivity of certain 
CEP procedures, however, has been improved to 
approach that of CF (11, 15, 19). Another disad-
vantage of CF tests is the scarcity of suitable antisera, 
since many antisera are of low titer and are anti-
complementary (AC). 
The hemagglutination-inhibition (HAI) test 
and the radioimmunoassay (RIA) procedures have 
been reported to be much more sensitive than the 
CEP and CF tests for the detection of both antigen 
and antibody. The comparative sensitivity of CEP 
and HAI is given in Table 3 as reported by Vyas 
et al. (23). Vyas and Shulman (22) estimated that 
HAI was 100 times more sensitive than AGD for 
the detection of HB Ag. In addition to its relatively 
high sensitivity, HAI has the advantage of simplicity. 
Not all batches of antigen are satisfactory for coating 
the reagent red cells, however, and some lots of anti-
TABLE 2 
RELATIVE SENSITIVITY OF TESTS FOR A USTRALIA ANTIGEN IN REFERENCE TO GEL 0IFFUS!ON 
Test 
Agar gel diffusion 
Electron microscopy 
Electroimmunodiffusion 
a. Immunoelectrodiffusion 
b. Tmmunoelectroosmophoresis 
c. Counterelectrophoresis 
Immunoelectronmicroscopy 
Complement-fixation 
Hemagglutination inhibition 
Radioimmunoassay 
Radioimmunoassay (solid phase) 
Relative Sensitivity 
1.0 
I. 5 
10 .0 
11.0 
100.0 
1000.0 
1000.0 
600.0 
Time 
24 hrs. 
2-6 hrs. 
! -3 hrs. 
2-6 hrs. 
16 hrs. 
2-4 hrs. 
5 days 
2-4 hrs. 
Reference 
Blumberg and Alter (4) 
Almeida and Waterson ( I) 
Duquesnoy and Becker (8) 
Prince ( 17) 
Gocke and Howe (10) 
Almeida and Waterson (I) 
Shulman and Barker (21) 
Vyas and Shulman (22) 
Lander. et al. ( 13) 
Cawley (5) 
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TABLE 3 
COMPARISON OF CEP AND HAI FOR HB AG TESTING ON 
SERA OF 700 PATIENTS WITH CLINICAL HEPATITIS.* 
HAI+ 
HAI-
CEP+ 
201 
9 
CEP-
50 
440 
* The same goat anti-HB Ag was used for both CEP 
and HAI. 
serum are not suitable for agglutination and in-
hibition tests. 
A number of RIA techniques have been 
described. All utilize a radioiodinated marker, usually 
HB antigen or its antibody labeled with !125 . The 
Ausria-125® of Abbott seemed to be a promising 
technique because of its high sensitivity with potential 
screening of blood donors (14, 19). Recent studies, 
however, have revealed that there may be an in-
herent serious pitfall in this particular procedure ( 1). 
A small percentage of the reactions seems to be 
falsely positive thus necessitating further tests if mis-
labeling of individuals as carriers of HB Ag is to be 
avoided. 
Soon after reagents for the detection of HB Ag 
became commercially available, the Medical College 
of Virginia Blood Bank began screening donors by 
the AGD procedure. The Virology Laboratory at the 
Medical College of Virginia instituted the CF test 
using antiserum provided by NIH to test patients 
suspected of having viral hepatitis. When CEP kits 
became available early in 1971, because of the low 
sensitivity of AGD, it was decided to conduct a study 
to evaluate the relative sensitivity of the new method; 
thus, each of 300 sera were tested by AGD, CF and 
CEP. The sera were obtained from patients sus-
pected clinically of having viral hepatitis. 
Some of the results of this initial study are 
given in Table 4 showing the relationship between 
CF titers and the reactions of the 300 sera in the 
AGD and CEP tests. Of the 300 sera tested, 22.3% 
were positive by CF, whereas 12% and 10.6% were 
positive by CEP and AGD, respectively. The highest 
serum dilution giving a positive reaction by AGD 
was 1 : 16, while CEP failed to detect dilutions higher 
than 1: 64. This study, like a number of others, in-
dicated that AGD is the least sensitive method and 
that CF is the most sensitive of the three techniques. 
The sensitivity of AGD in this study was some-
what higher than that reported by other workers. 
This enhancement was probably related to antiserum 
titer and the placement of patient sera adjacent to 
wells containing HB Ag-positive serum (reinforce-
ment pattern). Although this study did not provide 
evidence for a significant difference in the sensitivity 
of the CEP as compared to AGD, it was decided to 
abandon the latter procedure in favor of the former 
because the performance of CEP could be shortened 
to 60 minutes. 
A second study was then started around the 
middle of 1972 because, at the time, there were no 
reports in the literature on the relative sensitivity of 
the various commercial CEP methods that have be-
come available for routine HB Ag screening of 
donors and patients and because it was felt that a 
significantly more sensitive, yet relatively simple, 
technique was needed. Abbott's Ausria-J 25® was 
chosen for this purpose because it was reported to 
meet these criteria (14). It was hoped that the 
results of this comparative study would serve as a 
guide in selecting one of the six CE'P methods and/ or 
the RIA for donor screening. It was decided that a 
change from the CEP to the RIA technique should 
be made if the latter could be shown to be practical 
and devoid of false positive reactions. Since a reverse-
passive hemagglutination (RPHA) technique was 
available at that time, it was also included in these 
comparative studies. 
The Blood Bank routinely uses the CEP method 
of Spectra Biologicals to screen donors . Five other 
CEP methods used in this study were kindly supplied 
to us by Abbott Laboratories, Ortho Diagnostics, 
Pfizer, Squibb and Hyland. All CEP tests were per-
formed according to the manufacturers' instructions. 
In addition to CEP, Abbott kindly supplied us with 
the reagents for RPHA as well as the reagents and 
the gamma counter used with their RIA procedure. 
Again the prescribed protocol of the manufacturer 
was followed with one modification which consisted 
of a reduction in the incubation time of test sera with 
the antibody. The incubation time was reduced from 
i 6 hours to 90 minutes. 
Initially 90 sera were tested by the six CEP 
methods. Of these, 72 were derived from blood 
secured commercially, 11 were from donors sus-
pected of having Gilbert's disorder and the remain-
ing seven were from individuals known to be HB Ag 
positive on the basis of previous testing. As seen 
from Table 5, none of the sera from commercial 
blood donors or from donors with Gilbert's disorder 
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TABLE 4 
COMPLEMENT-FIXATION (CF) TITERS OF HEPATITIS B ANTIGEN (HB AG) AND REACTIONS OF 300 SERA IN lMMUNODIFFUSION (ID) 
AND CoUNTERELECTROPHORESIS (CEP) TESTS 
CF Titer of HB Ag 
Total No. of Sera Tested (22. 3% positive) 
233 < 1:2 
19 1 :2- 1 :8 
12 1 :16- 1 :32 
16 1 :64- 1 :128 
14 1 :256-1 :2048 
6 1 :4096-1 :16384 
gave a positive test. The seven sera previously known 
to be positive by Spectra CEP technique were posi-
tive again on retesting but the other five CEP pro-
cedures detected only six of these. Shortly after these 
tests were performed, kits for RIA and RPHA test-
ing were made available to us. At the same time, and 
by lucky coincidence, a panel of 20 sera arrived from 
the American Association of Blood Banks ( AABB) 
for proficiency and quality control testing. CEP and 
RIA results on these 20 sera are shown in Table 
6. AABB subsequently reported that 11 were posi-
tive. All 11 were detected by RIA and all but one 
were detected by Spectra CEP which at the time 
seemed to be the most sensitive of the CEP methods. 
Next in sensitivity appeared to be the Ortho and 
Pfizer CEP procedures, each of which detected nine 
of the 11 positives. The other methods showed rela-
tively poor sensitivity, failing to detect almost 50% 
of the positive sera. 
Testing of 204 serum samples, representing a 
mixed population of patients suspected of having 
viral hepatitis, and "normal" hospital employees, was 
then done by CF, RPHA, RIA and by the six CEP 
methods. Results are presented in Table 7. Among 
the six CEP methods, Ortho's proved to be the most 
sensitive while Abbott's was the least, failing to de-
No. of Sera Positive by 
CEP ID 
(12% of total) (10.6% of total) 
0 0 
0 0 
2 0 
14 12 
14 14 
6 6 
tect HB Ag in six sera. There was also a significant 
difference between Ortho's sensitivity and that of the 
other four CEP procedures each of which failed to 
detect the antigen in five sera. These findings and the 
fact that Ortho's method was nearly as sensitive as 
the CF test in the present series indicated that when 
the test conditions were adequate, relatively high 
sensitivity could be attained with the CEP procedure. 
Lewis and Coran ( 14) attributed the higher sensi-
tivity of the Ortho technique to the considerably 
larger volumes of test sera and antisera used in this 
method as compared to the others. Nevertheless, 
these results confirmed our previous findings, namely 
that generally, CEP methods are less sensitive than 
CF. These results also revealed that it is possible 
to get CEP positive-RIA negative results. These 
findings are in disagreement with those of Lewis and 
Coran ( 14) . 
The present study did not provide evidence that 
Abbott's RPHA method, a version of hemagglutina-
tion, is more sensitive than CF or Ortho's CEP. It 
was noted that RPHA results were more difficult to 
interpret, since the differences between weakly posi-
tive and negative reactions were not clear and could 
not provide for a clear-cut diagnostic reading. 
Like other studies ( 5, 13, 24), RIA appeared 
TABLE 5 
RESULTS OF TESTING 90 SERA BY SIX CEP PROCEDURES (A-F) 
Test Procedure & No. Positive Total No. 
Category of Donors A B c D E F Samples Tested 
Commercial 0 0 0 0 0 0 72 
MCV Known Positive 7 6 6 6 6 6 7 
Gilbert's 0 0 0 0 0 0 11 
CEP Methods: Spectra Hyland Ortho Pfizer Abbott Squibb 
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TABLE 6 
COMPARATIVE SENSITIVITY OF THE RIA WITH CEP PROCEDURES ON PROFICIENCY SAMPLES FOR DETECTION OF HB AG 
CEP System 
Total No. Samples* A B c 
8 6 7 
20 2 1 2 
10 7 9 
CEP Methods Spectra Hyland Ortho 
* Submitted by the AABB for quality control 
** Weakly 
to be the most sensitive technique, despite the fact 
that the CEP and CF procedures could detect a 
total of five positive sera which were negative by 
RIA; RIA, however, was the only procedure giving 
a positive reaction in all 11 sera (Table 7) . The 
higher sensitivity of this technique seemed to be 
further supported by testing 50 additional sera only 
by RIA Spectra and Ortho. As seen in Table 8, two 
sera failed to react by both Ortho's and Spectra's 
CEP but gave a positive RIA result. In this series, 
however, none of the sera positive by Spectra's 
and/ or Ortho's CEP methods was negative by RIA. 
In order to determine the specificity of the RIA 
positive reactions, two approaches were taken. First, 
three sera that were positive by RIA only were 
concentrated by lyphogel to see if these concentrates 
TABLE 7 
COMPARATIVE SENSITIVITY OF THE RIA WITH CEP, CF AND 
RPHA PROCEDURES FOR DETECTION OF HB AG 
(204 samples*) 
CEP Methods: A = Spectra B = H yland C = Ortho 
D = Pfizer E = Abbott F = Squibb 
CEP System CF RPHA RCA 
A B c D E F Test Test Test Results 
19 17 22 15 15 18 28 28 38 Positive 
3 5 5 7 6 4 W** Positive 
22 22 27 22 21 22 28 28 38 Total Positive 
2 0 . 4 0 0 Nonspecific 
1 1 0 0 0 0 Positive by one 
method only 
Proportion positive by one or more methods: 41 / 204 
* From a mixed population: "normal" hospital 
employees and patients suspected of having hepatitis. 
** Weakly 
D E F RIA Test Results 
6 4 5 11 Positive 
3 2 1 W** Positive 
9 6 6 11 Total Positive 
Pfizer Abbott Squibb 
would revert from negative to positive CEP on re-
testing. Only one of the three concentrated sera 
converted to positive by both CEP procedures; the 
other two sera remained negative. These results in-
dicated that some of the positive reactions were 
specific, thus implying that the nonreactivity of un-
concentrated sera by CEP was due to the lower 
sensitivity of this procedure as compared to that of 
RIA. The second approach consisted of testing double 
serial dilutions of five sera of known complement-
fixing titer by the two CEP methods and by RIA. 
AB serum known to be negative by Spectra's and 
Ortho's CEP methods and by RIA was used as a 
diluent (7). These sera had been frozen at -20°C 
for variable time periods up to several months. The 
results (Table 9) indicate that Ortho's CEP and 
Abbott's RIA are two-to-four times and 16-to-32 
times as sensitive as Spectra's CEP, respectively. 
These findings are in disagreement with those re-
ported by others who showed that RIA is 1 OO-to-
1000-fold more concentrative than CEP (5, 14, 24). 
The lower comparative sensitivity in this study may 
be due to the shorter incubation period. 
No correlation was found among CF, CEP and 
RIA titers. For example, serum # 5 with a CF titer 
of 1: 8, 192 had an RIA titer only one dilution higher 
than that of serum # 1 which had a CF titer of 
1: 128. Environmental factors, such as temperature 
and duration of storage as well as differences in 
handling of sera, might have been responsible for 
some of these changes. A second study was then 
conducted in which five freshly drawn samples (three 
known positive and two known negative) were tested 
in a similar fashion . The CF titer of the three positive 
sera was determined (Table 10) . 
Unfortunately, the RIA results were erratic and 
difficult to explain. For example, positive serum #2 
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TABLE 8 
COMPARISON OF RESULTS OBTAINED BY RIA 
AND 0RTHO AND SPECTRA CEP METHODS 
(50 samples) 
No. % Ort ho Spectra 
of Tests of Tests RIA CEP CEP 
·----
41 82 0 0 0 
4 8 + + + 
3 6 + + 0 
2 4 + 0 0 
% Total 100 18 14 8 
reacted first, at dilutions 1 :64 and 1: 128 . Negative 
results followed for seven serial dilutions to appear 
positive again at a dilution of 1: 32, 768. Analogous 
results were obtained with the presumably negative 
sera #4 and #5. Serum #4 was negative when 
tested, undiluted and at 1: 2 and 1 : 8 dilutions, but 
it was positive at 1 :4 and 1: 16. Serum #5 reacted 
at a 1: 4 dilution but was negative undiluted and 
when tested at 1:2, 1:8 and 1:16. 
It has been reported that when normal human 
sera are used as diluent they may enhance reactivity 
of positive sera ( 6). This, however, does not explain 
the erratic behavior of the RIA test in this series. 
A technical error cannot be excluded entirely as the 
possible cause and would suggest that this tech-
nique may be too exacting to be used as a screening 
procedure. This could conceivably be responsible for 
at least some of the false positive reactions described 
in the last series. 
Since not all RIA positive-CEP negative sera 
became positive after concentration and in view of 
the erratic results obtained in the last series, it is 
impossible to ascertain the specificity of all RIA 
positive reactions . This cautious statement is con-
sistent with a recent report which described the oc-
currence of false positive reactions using Abbott's 
RIA technique. It was demonstrated that reactivity 
of an antibody present in human serum directed 
against a guinea pig protein was responsible ( 2). 
TABLE 9 
TITER OF FIVE HB Ao PosmvE SERA* BY CEP (SPECTRA & ORTHo) AND BY RIA 
Method 1 Method 2 Method 3 Method 4 Method 5 
Serum CEP RIA CEP RIA CEP RIA CEP RIA CEP RIA 
Dilution A c A c A c A c A c 
Undiluted + + ND** + + ND + + ND + + ND + + ND 
1 :2 + + ND + + ND + + ND + + ND + + ND 
1 :4 + + ND + + ND w+ + + + + ND + + ND 
1 :8 + + ND + + ND - + + + + ND + + ND 
I :16 + + + W+***+ + - - + + + ND + + ND 
1 :32 - + + - + + - - + + + ND + + ND 
1 :64 - + + - - + - - + + + ND w+ + + 
Undiluted - - + - - + - - + w+ + + - + + 
1 :256 - - + - - + - - - - + + - - + 
1:512 - - + - - - - - - - - + - - + 
1 :1024 - - - - - - - - - - - + - - + 
1 :2048 - - + - - + 
I :4096 - - - - - -
1 :8192 - - - - - -
1 :16384 - - - - - -
1 :32,768 - - - - - -
CF Titer 1 :128 1 :512 1 :512 1 :8192 1 :8192 
* The five sera in this experiment have been frozen for various time periods at - 20 °C. The above CF titers were those obtained 
on the fresh samples prior to freezing. 
* * ND = not done. 
*** w + = weakly positive. 
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TABLE JO 
TITERS OF FIVE FRESH HB Ao PosmvE SERA BY CEP (SPECTRA & 0RTHo) AND BY RIA 
Serum 1 Serum 2 Serum 3 Serum 4 Serum 5 
Serum CEP RIA CEP RIA CEP RIA CEP RIA CEP RIA 
Dilution A c A c A c A c A c 
Undiluted + ND* + + ND + + ND - - - - - -
I :2 + + ND + + ND + + ND - - - - - -
I :4 + + ND + + ND + + ND - - + - - + 
1 :8 W+** + ND + + ND + + ND - - - - - -
1: 16 - + + + + ND w+ + + - - + - - -
1 :32 - - + + + ND -
I :64 - - + w + + + -
1 :128 - - + w+ + + -
1 :256 - - + - - - -
I :512 - - - - - - -
1 :1024 - - - - - - -
1 :2048 - - - -
1:4096 - - - -
1 :8192 - - - -
1 :16384 - - - -
1 :32,768 - - + -
CF Titer I :128 I 1 :512 
* ND = not done. 
* * W + = weakly positive. 
Until further tests can be performed to demonstrate 
the presence of HB Ag in the RIA positive-CEP 
negative sera by other methods designed to eliminate 
the human antiguinea pig protein interference, the 
positivity of these sera must remain suspect. 
In conclusion, this study supports the claim 
that the RIA is the most sensitive of all assay 
methods for detection of HB Ag in use today. Be-
cause of the inability to verify the presence of HB 
Ag in those sera positive by RIA alone, however, 
this claim must be taken only at face value. Further 
studies are needed to confirm the specificity of these 
positive reactions. 
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